What is the postpartum management for an Rh (Rhesus) negative mother, particularly in terms of preventing sensitization to Rh positive blood?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 24, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Postpartum Management for Rh Negative Mothers

All Rh-negative mothers must receive RhD immune globulin (RhIg) within 72 hours after delivery of an Rh-positive infant to prevent devastating hemolytic disease in future pregnancies. 1, 2

Immediate Postpartum Protocol

Step 1: Confirm Infant's Blood Type

  • Determine the newborn's Rh status immediately after delivery 2
  • If the infant is Rh-positive or blood type cannot be determined, proceed with RhIg administration 2
  • If paternity is certain and the father is confirmed Rh-negative, RhIg is not needed 3

Step 2: Verify Mother's Eligibility

Before administering RhIg, confirm: 2

  • Mother is Rh-negative
  • Mother is not already sensitized (no anti-D antibodies present)
  • Infant has a negative direct antiglobulin test (DAT)

Step 3: Administer Standard Dose Within 72 Hours

Give 300 μg (1,500 IU) of RhIg intramuscularly or intravenously within 72 hours of delivery. 1, 3 This single postpartum dose reduces alloimmunization from 12-13% down to 1-2%. 1, 2 When combined with the antenatal dose given at 28 weeks, protection increases further to 99.8-99.9% (reducing alloimmunization to 0.1-0.2%). 1

Critical Timing Considerations

The 72-hour window is optimal but not absolute: 4, 5

  • Administer as soon as possible after delivery for maximum effectiveness 3, 6
  • If the 72-hour window is missed, still give RhIg up to 28 days postpartum—delayed administration provides some protection and is far better than no administration 1, 3
  • Between 72 hours and 13 days is reasonable; up to 28 days is still recommended in special circumstances 6, 7

Screening for Excessive Fetomaternal Hemorrhage

When to Test for Large FMH

Consider quantitative testing for fetomaternal hemorrhage in these high-risk scenarios: 3

  • Placental abruption
  • Blunt abdominal trauma during pregnancy
  • Placenta previa with significant bleeding
  • Manual removal of placenta
  • Stillbirth

Four-Step Testing Protocol (U.S. Standard)

Step 1: Perform rosette screen to detect excessive FMH (>30 mL fetal whole blood) 8

Step 2: If rosette screen is negative, give standard single dose of 300 μg RhIg 8

Step 3: If rosette screen is positive, perform quantitative testing (Kleihauer-Betke acid-elution assay or flow cytometry) 8

Step 4: Calculate additional RhIg needed: 3, 6

  • Standard 300 μg dose covers up to 15 mL of fetal red blood cells (30 mL fetal whole blood)
  • For excess FMH, give additional 10 μg RhIg per 0.5 mL of fetal RBCs beyond the amount covered 3, 6
  • The formula includes a precautionary extra vial in borderline situations to prevent underdosing 8

Important Note on Antenatal Dosing

If the mother received antenatal RhIg at 28 weeks, she still requires the full postpartum dose if she delivers an Rh-positive infant. 2 The antenatal dose does not eliminate the need for postpartum prophylaxis—both doses are essential for optimal protection. 1

Common Pitfalls to Avoid

  • Don't skip postpartum RhIg if antenatal dose was given—both doses are required for the two-dose protocol that achieves 99.8% protection 1
  • Don't assume ABO incompatibility provides protection—while ABO incompatibility offers some natural protection, RhIg should still be administered 9
  • Don't withhold RhIg if infant's blood type is unknown—treat as Rh-positive and administer prophylaxis 2, 6
  • Don't give RhIg to mothers with "weak D" (Du-positive)—these women are considered Rh-positive and don't need prophylaxis 3
  • Don't forget to obtain informed consent—RhIg is a blood product requiring verbal or written consent before administration 3

Documentation Requirements

Document the following in the medical record: 3

  • Mother's Rh-negative status and antibody screen results
  • Infant's Rh-positive status (or unknown status)
  • Time and date of RhIg administration
  • Dose administered (including any additional doses for excessive FMH)
  • Informed consent obtained

References

Guideline

Management Guidelines for Rh Negative Pregnancy

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Prevention of Rh alloimmunization.

Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC, 2003

Guideline

Rh Alloimmunization Timeframe and Prevention

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

RhoGAM Administration Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Postpartum Rh immunoprophylaxis.

Obstetrics and gynecology, 2012

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.